Stockscreener 앱 받기
0.9501
0.77%
-0.0074
시간 외 거래:
.95
-0.000100
-0.01%
전일 마감가:
$0.9575
열려 있는:
$0.95
하루 거래량:
1.69M
Relative Volume:
0.48
시가총액:
$273.49M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-2.5678
EPS:
-0.37
순현금흐름:
$-72.53M
1주 성능:
-1.37%
1개월 성능:
-5.93%
6개월 성능:
-28.56%
1년 성능:
+146.78%
1일 변동 폭
$0.93
$0.96
1주일 범위
$0.9032
$1.02
52주 변동 폭
$0.351
$2.105
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
오큐젠 Stock (OCGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | 개시 | Mizuho | Buy |
| 2022-06-15 | 재개 | ROTH Capital | Buy |
| 2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-07-26 | 개시 | Noble Capital Markets | Outperform |
| 2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Vanguard Group Inc's Strategic Acquisition of Shares in Ocugen I - GuruFocus.com
Ocugen to Spotlight Gene Therapy Advances at Upcoming Clinical Showcase - MSN
Ocugen (OCGN) Set to Announce Earnings on Friday - MarketBeat
Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163% - Yahoo Finance
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 - Ocugen
Ocugen Clinical Showcase Highlighting Progress in Retinal - GlobeNewswire
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy - MSN
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
HC Wainwright Reiterates Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease - Ocugen
Ocugen advances to phase 2 in Stargardt disease trial - Investing.com
Data and Safety Monitoring Board Approves Initiation of - GlobeNewswire
Ocugen to Host Conference Call on Friday, November 8 at - GlobeNewswire
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results - StockTitan
State Street Corp's Strategic Acquisition of Shares in Ocugen Inc - Yahoo Finance
Ocugen Inc. stock outperforms market despite losses on the day - MarketWatch
Maxim Group sees Ocugen shares as a buy, cites financial position - Investing.com
Ocugen (NASDAQ:OCGN) Receives New Coverage from Analysts at Maxim Group - MarketBeat
Ocugen Advances Promising Pipeline Amid Financial Restraints - Nasdaq
Ocugen’s CEO to Present at 2024 Maxim Healthcare Virtual Summit - MSN
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit - Ocugen
Ocugen says FDA has removed clinical hold on eye drug OCU200 - MSN
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial - Ocugen
FDA lifts hold on Ocugen's DME drug trial - Investing.com
Ocugen Says FDA Lifts Clinical Hold on Diabetic Macular Edema Drug - MarketWatch
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for - The Bakersfield Californian
Ocugen, Inc. Announces Removal of Clinical Hold on - GlobeNewswire
Ocugen, Inc. to Feature at Chardan’s Genetic Medicines Conference - MSN
WashU COVID-19 nasal vaccine technology licensed to Ocugen - WashU Medicine
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Cheese Block (BGU25) Quote - The Globe and Mail
Ocugen, Inc. Set to Present at 2024 Cell & Gene Meeting on the Mesa - MSN
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa - Ocugen
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Profund Advisors LLC Invests $227,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference - MSN
Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares - openPR
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):